NEW MJ NEWS

HEXO to Begin Trading on the Nasdaq

HEXO Corp (“HEXO” or the “Company”) (TSX: HEXO; NASDAQ: HEXO) today announced that the previously announced transfer of its stock exchange listing to the Nasdaq Capital Market (“Nasdaq”) from the New York Stock Exchange is complete.

The Company’s common share will begin trading as a Nasdaq-listed security at market open today, August 24, 2021. Current retail and institutional investor shares will automatically be transferred over to Nasdaq. Current shareholders are not required to take any action.

About HEXO

HEXO is an award-winning licensed producer of innovative products for the global cannabis market. HEXO serves the Canadian recreational market with a brand portfolio including HEXO, UP Cannabis, Original Stash, Bake Sale, Namaste, and REUP brands, and the medical market in Canada, Israel and Malta. The Company also serves the Colorado market through its Powered by HEXO® strategy and Truss CBD USA, a joint venture with Molson Coors. In the event that the previously announced transactions to acquire 48North and Redecan close, HEXO expects to be the number one cannabis products company in Canada by recreational market share.

For more information, please visit www.hexocorp.com.

Investor Relations:

invest@HEXO.com

www.hexocorp.com

Media Relations:

(819) 317-0526

media@hexo.com


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

PotNetwork Holding, Inc. (POTN) Engages PCAOB Registered CPA Firm to Initiate Audit

PCAOB Registered CPA Firm Engaged to Initiate Audit on PotNetwork Holding, Inc.’s…

$TURV Shareholders to Earn 2,500,000 GrowCo Dividend Shares

Two Rivers Shareholders to Earn 2,500,000 GrowCo Dividend Shares, Construction of First…

Neptune Wellness Solutions Inc. (NEPT) Announces a Definitive Agreement with International Flavors & Fragrances

Neptune Announces a Definitive Agreement with International Flavors & Fragrances to Co-Develop…

$CARA Initiates Phase 2 Trial of Oral CR845 in Osteoarthritis

Cara Therapeutics Initiates Phase 2 Trial of Oral CR845 in Osteoarthritis Trial…